Translate Bio to Present at the SVB Leerink Virtual 10th Annual Global Healthcare Conference

Rhea-AI Summary

Translate Bio (Nasdaq: TBIO), a clinical-stage mRNA therapeutics company, announced CEO Ronald Renaud's participation in a fireside chat at the SVB Leerink Virtual 10th Annual Global Healthcare Conference on February 26, 2021, at 9:20 a.m. EST. This event highlights the company's focus on transformative mRNA medicines aimed at treating life-threatening diseases, particularly pulmonary diseases like cystic fibrosis. Interested parties can access the live webcast via the company's website, with archived replays available for 30 days.

News Market Reaction – TBIO

-7.11%

-7.11% Session move

In the trading session that priced this news, TBIO declined 7.11%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

LEXINGTON, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat or prevent debilitating or life-threatening diseases, today announced that Ronald Renaud, chief executive officer, will participate in a fireside chat at the SVB Leerink Virtual 10th Annual Global Healthcare Conference on Friday, February 26, 2021 at 9:20 a.m. EST.

A live webcast of the session will be accessible through the “Events and Presentations” page of the Company's website at investors.translate.bio. A replay of the webcasts will be archived on the Translate Bio’s website for 30 days following the presentation.

About Translate Bio
Translate Bio is a clinical-stage mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, or to prevent infectious diseases by generating protective immunity. Translate Bio is primarily focused on applying its technology to treat pulmonary diseases with a lead pulmonary candidate being evaluated as an inhaled treatment for cystic fibrosis (CF) in a Phase 1/2 clinical trial. Additional pulmonary diseases are being evaluated in discovery-stage research programs that utilize a proprietary lung delivery platform. Translate Bio also believes its technology may apply broadly to a wide range of diseases, including diseases that affect the liver. Additionally, the platform may be applied to various classes of treatments, such as therapeutic antibodies or protein degradation. Translate Bio is also pursuing the development of mRNA vaccines for infectious diseases under a collaboration with Sanofi Pasteur.

Contacts for Translate Bio

Investors Teri Dahlman tdahlman@translate.bio 617-817-8655

Media Maura Gavaghan mgavaghan@translate.bio  617-233-1154

FAQ

When is Translate Bio's CEO participating in the SVB Leerink Conference?

Ronald Renaud will participate in the SVB Leerink Virtual 10th Annual Global Healthcare Conference on February 26, 2021, at 9:20 a.m. EST.

How can I watch the Translate Bio conference live?

The live webcast of the conference can be accessed through the 'Events and Presentations' page on Translate Bio's website.

What is the focus of Translate Bio's research?

Translate Bio is focused on developing mRNA therapeutics to treat diseases caused by protein or gene dysfunction, with an emphasis on pulmonary diseases.

What is Translate Bio's lead clinical candidate?

The lead clinical candidate is an inhaled treatment for cystic fibrosis, currently in a Phase 1/2 clinical trial.

Is Translate Bio developing mRNA vaccines?

Yes, Translate Bio is pursuing the development of mRNA vaccines for infectious diseases in collaboration with Sanofi Pasteur.